drugset / Trial / NCT05811247

Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)

NCT05811247

Phase 3 Completed 660 enrolled Apnimed
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.

Timeline

Start
2023-08-28
Primary completion
2025-05-07
Completion
2025-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AD109 Unknown Oral